Hayatudeen Muhammad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hayatudeen Muhammad has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Sodeeq Babalola
Ahmadu Bello University
3 shared publications - Abdullahi Idris
Department of Pharmaceutical and Medicinal Chemistry, Ahmadu Bello University, Zaria 810211, Nigeria
2 shared publications - Asmau Nasiru Hamza
Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Ahmadu Bello University, Zaria 810107, Kaduna State, Nigeria
2 shared publications Abdullahi Y. Idris
Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Ahmadu Bello University, Zaria, Nigeria
1 shared publicationAliyu M. Musa
Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Ahmadu Bello University, Zaria, Nigeria
1 shared publicationAmina B. Olorukooba
Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Ahmadu Bello University, Zaria, Nigeria
1 shared publication
Latest Publications
- Open Access
- 24 May 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Analysis of multi-target directed novel non-peptidic chalcone scaffold as potential malaria plasmodium proteases inhibitors
Malaria remain an epidermic infectious disease that is ravaging the world most especially sub-Sahara Africa. Due to the prevalence of Plasmodium parasites that are resistant to first-line antimalarial drugs, it is urgently necessary to create new scaffolds and find strategies to overcome drug resistance. Chalcones are well-known, uncomplicated analogs that may be easily produced using a variety of techniques and are widely present in natural products. Utilizing in silico tools, we developed new antimalarial agents from active synthetic and natural product fragments, and then we assessed their pharmacokinetics and pharmacodynamic profiles as therapeutic molecules against the biological targets of the parasite that causes the deadly type of malaria. In this research, active fragments from prenylated and quinolinyl chalcones with known antimalarial characteristics were combined via molecular hybridization. Four enzymes that have been implicated to the spread of malaria are used as the biological targets in the docking simulation for the ligands (prenylated-quinolinyl chalcone hybrids). Receptor-ligand complexes were viewed using Discovery Studio Visualizer 2017 and Chimera. Web-based tools (Moftsoft, SwissADME, Admetlab, and AdmetSAR 1 and 2) were utilized for drug-likeness and ADME prediction. The hybridized active segments created a brand-new scaffold with 169 new prenylated-quinolinyl chalcones. Post-docking studies found significant interactions between the drugs and the used targets. At least 25 of the compounds exhibit high affinities for the targets (-9.4 to -7.5 kcal/mol-1). The selected compounds had interesting ADME and drug-like properties. The compounds were qualified as possible antimalarial drugs due to their realistic pharmacokinetic and pharmacodynamic characteristics as well as their prospective antimalarial activity.
- 24 May 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessAnalysis of multi-target directed novel non-peptidic chalcone scaffold as potential malaria plasmodium proteases inhibitors
Malaria remain an epidermic infectious disease that is ravaging the world most especially sub-Sahara Africa. Due to the prevalence of Plasmodium parasites that are resistant to first-line antimalarial drugs, it is urgently necessary to create new scaffolds and find strategies to overcome drug resistance. Chalcones are well-known, uncomplicated analogs that may be easily produced using a variety of techniques and are widely present in natural products. Utilizing in silico tools, we developed new antimalarial agents from active synthetic and natural product fragments, and then we assessed their pharmacokinetics and pharmacodynamic profiles as therapeutic molecules against the biological targets of the parasite that causes the deadly type of malaria. In this research, active fragments from prenylated and quinolinyl chalcones with known antimalarial characteristics were combined via molecular hybridization. Four enzymes that have been implicated to the spread of malaria are used as the biological targets in the docking simulation for the ligands (prenylated-quinolinyl chalcone hybrids). Receptor-ligand complexes were viewed using Discovery Studio Visualizer 2017 and Chimera. Web-based tools (Moftsoft, SwissADME, Admetlab, and AdmetSAR 1 and 2) were utilized for drug-likeness and ADME prediction. The hybridized active segments created a brand-new scaffold with 169 new prenylated-quinolinyl chalcones. Post-docking studies found significant interactions between the drugs and the used targets. At least 25 of the compounds exhibit high affinities for the targets (-9.4 to -7.5 kcal/mol-1). The selected compounds had interesting ADME and drug-like properties. The compounds were qualified as possible antimalarial drugs due to their realistic pharmacokinetic and pharmacodynamic characteristics as well as their prospective antimalarial activity.
- Open Access
- 15 March 2023
- Published by Georg Thieme Verlag KG in Pharmaceutical Fronts
- Vol. 05 (01) , e15-e24
Therapeutic Potency of Mono- and Diprenylated Acetophenones: A Case Study of In-Vivo Antimalarial Evaluation
Malaria remains a febrile infection of public health concern in many countries especially tropical countries in Africa and certain countries in Southern and North America such as Brazil, Costa Rica, Mexico, Dominican Republic, Colombia, and Ecuador. Hence this has made research into this area paramount. Acetophenones are active fragments in many compounds with promising antimalarial activity, such as chalcones. The aim of the present study was to investigate antimalarial activity of 3,5-diprenyl acetophenone (I) and 5-diprenyl acetophenone (II) in in vivo. In this study, compounds I and II were synthesized using an aromatic substitution reaction. The in-vivo antimalarial potential of compounds I and II was analyzed in Plasmodium berghei-infected mice. Our data showed that compound I (25, 50, and 100 mg/kg) had promising antimalarial activity, with parasitemia inhibited rate being 68.03, 65.16, and 69.75%, respectively. Compound II dose-dependently inhibited parasitemia levels, it demonstrated an infinitesimally higher activity (72.12%) when compared with compound I (69.75%) at 100 mg/kg dose. The two compounds passed the rule of three, Lipinski's rule of five, predicted plausible pharmacokinetic profile (ADME), and apparent safety profile, and demonstrated drug-like fragments. The study provided guidance in exploring novel antimalarial compounds based on the scaffolds of prenylated acetophenones.
- 15 March 2023
- Published by Georg Thieme Verlag KG in Pharmaceutical Fronts
- Vol. 05 (01) , e15-e24
Open AccessTherapeutic Potency of Mono- and Diprenylated Acetophenones: A Case Study of In-Vivo Antimalarial Evaluation
Malaria remains a febrile infection of public health concern in many countries especially tropical countries in Africa and certain countries in Southern and North America such as Brazil, Costa Rica, Mexico, Dominican Republic, Colombia, and Ecuador. Hence this has made research into this area paramount. Acetophenones are active fragments in many compounds with promising antimalarial activity, such as chalcones. The aim of the present study was to investigate antimalarial activity of 3,5-diprenyl acetophenone (I) and 5-diprenyl acetophenone (II) in in vivo. In this study, compounds I and II were synthesized using an aromatic substitution reaction. The in-vivo antimalarial potential of compounds I and II was analyzed in Plasmodium berghei-infected mice. Our data showed that compound I (25, 50, and 100 mg/kg) had promising antimalarial activity, with parasitemia inhibited rate being 68.03, 65.16, and 69.75%, respectively. Compound II dose-dependently inhibited parasitemia levels, it demonstrated an infinitesimally higher activity (72.12%) when compared with compound I (69.75%) at 100 mg/kg dose. The two compounds passed the rule of three, Lipinski's rule of five, predicted plausible pharmacokinetic profile (ADME), and apparent safety profile, and demonstrated drug-like fragments. The study provided guidance in exploring novel antimalarial compounds based on the scaffolds of prenylated acetophenones.
- Open Access
- 29 March 2022
- Published by MDPI AG in Preprints.org
Synthesis and Spectroscopic Studies of Novel Dichloro and Polymethoxy P-Nitrophenyl Hydrazones: A Comparative Study
We conducted a comparative study on the development of two synthetic methods. The solvent-free synthesis is a green chemistry method developed in a bid to ameliorate environmental adverse effects of the conventional solvent-based synthesis. The synthesis of novel dichloro and polymethoxy p-nitrophenylhydrazones through solvent free technique gave moderate to high yields which were however lower than those of the solvent-based method. The established solvent-free approach has several benefits, including universality and simplicity of the approach, catalyst-free conditions, non-use of an organic solvent, quick reaction time, fast and efficient workup, and un-solvated pure products in moderate to high yields.
- 29 March 2022
- Published by MDPI AG in Preprints.org
Open AccessSynthesis and Spectroscopic Studies of Novel Dichloro and Polymethoxy P-Nitrophenyl Hydrazones: A Comparative Study
We conducted a comparative study on the development of two synthetic methods. The solvent-free synthesis is a green chemistry method developed in a bid to ameliorate environmental adverse effects of the conventional solvent-based synthesis. The synthesis of novel dichloro and polymethoxy p-nitrophenylhydrazones through solvent free technique gave moderate to high yields which were however lower than those of the solvent-based method. The established solvent-free approach has several benefits, including universality and simplicity of the approach, catalyst-free conditions, non-use of an organic solvent, quick reaction time, fast and efficient workup, and un-solvated pure products in moderate to high yields.